# Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)

> **NCT00050817** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 15603 (actual)

## Conditions studied

- Arteriosclerosis

## Interventions

- **DRUG:** clopidogrel (SR25990)

## Key facts

- **NCT ID:** NCT00050817
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** —
- **Final completion:** 2005-08
- **Target enrollment:** 15603 (ACTUAL)
- **Last updated:** 2012-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00050817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00050817, "Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00050817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*